Kezar Competitors

KZR Stock  USD 0.82  0.07  7.87%   
Kezar Life Sciences competes with Century Therapeutics, Mineralys Therapeutics,, Nkarta, Surrozen, and Bolt Biotherapeutics; as well as few others. The company runs under Biotechnology sector within Health Care industry. Analyzing Kezar Life competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Kezar Life to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Kezar Life Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Kezar Life competition on your existing holdings.
  
As of 10/19/2024, Return On Tangible Assets is likely to drop to -0.48. In addition to that, Return On Capital Employed is likely to drop to -0.54. At this time, Kezar Life's Net Tangible Assets are relatively stable compared to the past year. As of 10/19/2024, Non Currrent Assets Other is likely to grow to about 5.9 M, while Non Current Assets Total are likely to drop slightly above 7.9 M.
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Kezar Life's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.040.837.22
Details
Intrinsic
Valuation
LowRealHigh
0.193.8510.24
Details
Naive
Forecast
LowNextHigh
0.010.737.13
Details
6 Analysts
Consensus
LowTargetHigh
11.8313.0014.43
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Kezar Life. Your research has to be compared to or analyzed against Kezar Life's peers to derive any actionable benefits. When done correctly, Kezar Life's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Kezar Life Sciences.

Kezar Life Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Kezar Life and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Kezar and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Kezar Life Sciences does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
NGMNKTX
CGEMNKTX
LRMRIPSC
BOLTIPSC
LYELIPSC
NKTXIPSC
  
High negative correlations   
KROSBOLT
SRZNNKTX
SRZNNGM
LYELKROS
KROSNKTX
KROSNGM

Risk-Adjusted Indicators

There is a big difference between Kezar Stock performing well and Kezar Life Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Kezar Life's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
IPSC  3.87 (0.93) 0.00 (0.22) 0.00 
 6.41 
 23.66 
MLYS  2.66  0.04  0.02  0.12  4.75 
 5.89 
 27.14 
NKTX  3.70 (0.75) 0.00 (0.30) 0.00 
 6.50 
 24.02 
NGM  3.76 (0.51) 0.00  0.53  0.00 
 6.16 
 24.21 
SRZN  3.72  0.10  0.03  0.16  4.45 
 8.70 
 24.97 
BOLT  1.41 (0.28) 0.00 (0.42) 0.00 
 3.08 
 11.37 
LRMR  3.27 (0.35) 0.00 (0.10) 0.00 
 4.64 
 24.09 
KROS  2.08  0.31  0.13  0.39  2.04 
 4.63 
 13.60 
LYEL  4.34 (0.66) 0.00 (0.09) 0.00 
 12.10 
 28.28 
CGEM  2.57 (0.24) 0.00 (0.06) 0.00 
 6.13 
 17.59 

Cross Equities Net Income Analysis

Compare Kezar Life Sciences and related stocks such as Century Therapeutics, Mineralys Therapeutics,, and Nkarta Inc Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
IPSC(246 M)(246 M)(246 M)(246 M)(246 M)(246 M)(246 M)(246 M)(246 M)(246 M)(54.7 M)(95.8 M)(130.9 M)(136.7 M)(143.5 M)
MLYS(3.4 M)(3.4 M)(3.4 M)(3.4 M)(3.4 M)(3.4 M)(3.4 M)(3.4 M)(3.4 M)(3.4 M)(3.4 M)(19.4 M)(29.8 M)(71.9 M)(68.3 M)
NKTX(274.5 K)(274.5 K)(274.5 K)(274.5 K)(274.5 K)(274.5 K)(274.5 K)(274.5 K)(274.5 K)(22.9 M)(50.4 M)(83.9 M)(119.4 M)(117.5 M)(111.6 M)
SRZN(24.4 M)(24.4 M)(24.4 M)(24.4 M)(24.4 M)(24.4 M)(24.4 M)(24.4 M)(24.4 M)(24.4 M)(32.6 M)(52.5 M)(27.7 M)(43 M)(45.2 M)
BOLT(11.6 M)(11.6 M)(11.6 M)(11.6 M)(11.6 M)(11.6 M)(11.6 M)(11.6 M)(11.6 M)(30 M)(72.3 M)(104.4 M)(85.9 M)(69.2 M)(72.7 M)
LRMR(36.6 M)(36.6 M)(36.6 M)(36.6 M)(36.6 M)(74.3 M)(57.9 M)(52 M)(61.4 M)(23.1 M)(42.3 M)(50.3 M)(34.2 M)(36.9 M)(38.8 M)
KROS(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.3 M)(1.3 M)(12.3 M)(45.4 M)(58.7 M)(104.7 M)(153 M)(145.3 M)
LYEL(121.3 M)(121.3 M)(121.3 M)(121.3 M)(121.3 M)(121.3 M)(121.3 M)(121.3 M)(121.3 M)(121.3 M)(198.5 M)(285.5 M)(4.8 M)(234.6 M)(246.4 M)
CGEM(704.7 K)(704.7 K)(704.7 K)(704.7 K)(130.5 K)(109.5 K)(316.7 K)(14.2 M)(14.2 M)(20 M)(50.8 M)(65 M)111.2 M(153.2 M)(145.5 M)
GLUE(8 M)(8 M)(8 M)(8 M)(8 M)(8 M)(8 M)(8 M)(8 M)(8 M)(36.1 M)(71.9 M)(104.6 M)(135.4 M)(128.6 M)
RVMD(31.1 M)(31.1 M)(31.1 M)(31.1 M)(31.1 M)(31.1 M)(31.1 M)(31.1 M)(41.8 M)(47.7 M)(108.2 M)(179.8 M)(248.7 M)(436.4 M)(414.5 M)
FHTX(26.3 M)(26.3 M)(26.3 M)(26.3 M)(26.3 M)(26.3 M)(26.3 M)(26.3 M)(26.3 M)(51.7 M)(69.8 M)(103.2 M)(108.9 M)(98.4 M)(103.3 M)
STTK(7.4 M)(7.4 M)(7.4 M)(7.4 M)(7.4 M)(7.4 M)(7.4 M)(7.4 M)(7.4 M)(23.9 M)(35.4 M)(44.3 M)(100.6 M)(87.3 M)(82.9 M)
KYMR(21.5 M)(21.5 M)(21.5 M)(21.5 M)(21.5 M)(21.5 M)(21.5 M)(21.5 M)(21.5 M)(41.3 M)(43.9 M)(98 M)(151.8 M)(147 M)(139.6 M)
NRIX(9.4 M)(9.4 M)(9.4 M)(9.4 M)(9.4 M)(9.4 M)(9.4 M)(9.4 M)(21.7 M)(43.2 M)(117.2 M)(166 M)(143.9 M)(129.6 M)(136 M)
DSGN(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(2 M)(8.3 M)(35.5 M)(58.6 M)(66.9 M)(63.5 M)
HOWL(11 M)(11 M)(11 M)(11 M)(11 M)(11 M)(11 M)(11 M)(11 M)(11 M)(14.9 M)(49.8 M)(51.6 M)(37.4 M)(39.2 M)
IKNA(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(16.8 M)(44.3 M)(34.1 M)(66.6 M)(68.2 M)(71.6 M)
STOK(5.6 M)(5.6 M)(5.6 M)(5.6 M)(5.6 M)(5.6 M)(5.6 M)(5.6 M)(12.5 M)(28.5 M)(50.6 M)(84.7 M)(93.1 M)(104.7 M)(99.5 M)

Kezar Life Sciences and related stocks such as Century Therapeutics, Mineralys Therapeutics,, and Nkarta Inc Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Kezar Life Sciences financial statement analysis. It represents the amount of money remaining after all of Kezar Life Sciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Kezar Life Competitive Analysis

The better you understand Kezar Life competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Kezar Life's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Kezar Life's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
KZR IPSC MLYS NKTX NGM SRZN BOLT LRMR KROS LYEL
 7.87 
 0.82 
Kezar
 1.91 
 1.60 
Century
 3.75 
 14.40 
Mineralys
 6.50 
 4.26 
Nkarta
 5.30 
 2.50 
NGM
 1.23 
 9.88 
Surrozen
 1.56 
 0.63 
Bolt
 1.15 
 7.76 
Larimar
 0.26 
 61.25 
Keros
 0.85 
 1.17 
Lyell
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Price To Book
Retained Earnings
Current Asset
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Total Debt
Return On Equity
Z Score
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Debt To Equity
Short Ratio
Target Price
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Relative Strength Index
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Kezar Life Competition Performance Charts

Five steps to successful analysis of Kezar Life Competition

Kezar Life's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Kezar Life Sciences in relation to its competition. Kezar Life's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Kezar Life in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Kezar Life's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Kezar Life Sciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Kezar Life position

In addition to having Kezar Life in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Currency Funds Thematic Idea Now

Currency Funds
Currency Funds Theme
Funds or Etfs investing in a single currency or combination of currencies from different countries in order to replicate respective foreign exchange markets. The Currency Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Currency Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Kezar Stock Analysis

When running Kezar Life's price analysis, check to measure Kezar Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kezar Life is operating at the current time. Most of Kezar Life's value examination focuses on studying past and present price action to predict the probability of Kezar Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kezar Life's price. Additionally, you may evaluate how the addition of Kezar Life to your portfolios can decrease your overall portfolio volatility.